Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121468 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ROCK2ROCK1MTNR1A | |
| SCHEMBL12135489 | 0.95 | PTGS2 (0.38) | PTGS2PTGS1ROCK2ROCK1TDP1 | |
| SCHEMBL12135490 | 0.94 | PTGS2 (0.41) | PTGS2PTGS1ROCK2ROCK1MTNR1A | |
| SCHEMBL2870177 | 0.94 | ROCK2 (0.40) | PTGS2PTGS1ROCK2ROCK1MTNR1A | |
| SCHEMBL10121568 | 0.93 | PTGS2 (0.42) | PTGS2PTGS1ROCK2ROCK1MTNR1A | |
| SCHEMBL555105 | 0.89 | PTGS2 (0.41) | PTGS2PTGS1MTNR1AMTNR1BTDP1 | |
| SCHEMBL10121473 | 0.89 | PTGS2 (0.39) | PTGS2PTGS1ROCK2ROCK1TDP1 | |
| SCHEMBL12135562 | 0.89 | PTGS2 (0.39) | PTGS2PTGS1ROCK2ROCK1MTNR1A | |
| SCHEMBL12135318 | 0.89 | PTGS2 (0.40) | PTGS2PTGS1MTNR1AMTNR1BTDP1 | |
| SCHEMBL10121542 | 0.89 | PTGS2 (0.41) | PTGS2PTGS1MTNR1AMTNR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-8062653-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | PTGS2 59/4885PTGS1 27/4885ROCK2 1160/4885 |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | PTGS2 59/4885PTGS1 27/4885ROCK2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.